Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: House Ear Institute
• Collaborator: Cures Within Reach
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Adults 18 years of age or older

• Must meet all AAO-HNS 2020 criteria for definite Meniere's Disease

• Must have a skin test positive for allergy

• Is already a candidate for treatment with montelukast for allergic rhinitis/failed first line over-the-counter allergy treatments

Exclusion Criteria:

• Had a previous surgical procedure for treatment of vertigo

• Currently receiving any allergy immunotherapy or taking montelukast or a beta-blocker

• Pregnant or recent pregnancy ((≤ 8 weeks postpartum), or lactation)

• Current hospitalization for any reason

• Any active, acute, or chronic pulmonary disorder other than asthma

• History of intubation for asthma